Search clinical trials for: relapsed /refractory Hodgkin lymphoma

Total 13583 results

Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy
Hoffmann-La Roche

Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

Korea, Republic of, United States, China, Germany, Poland, Spain, Taiwan, United Kingdom, Australia, France, Belgium, Switzerland, Denmark, Puerto Rico
Beijing Tongren Hospital

Recruiting

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type

China
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
The First Affiliated Hospital with Nanjing Medical...
Guangzhou Lupeng Pharmaceutical Company LTD.; Newave Pharmaceutical Inc

Recruiting

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Non Hodgkin Lymphoma

China
Sun Yat-sen University

Recruiting

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma

China
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Memorial Sloan Kettering Cancer Center

Recruiting

Study of CAR-T Therapy in Older Patients

Lymphoma | Lymphoma, B-Cell | Multiple Myeloma | High-grade B-cell Lymphoma | Refractory B-Cell Lymphoma | DLBCL NOS

United States
Peking Union Medical College Hospital
Peking University Third Hospital; Dongzhimen Hospital, Beijing; Beijing Longfu...

Recruiting

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Cutaneous T-cell Lymphoma

China
Yan'an Affiliated Hospital of Kunming Medical University

Recruiting

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Beijing Tongren Hospital

Recruiting

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-cell

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Intense Monitoring Study on Tyvyt

Relapsed or Refractory Classical Hodgkin's Lymphoma

China
SciTech Development, LLC
Rush University Medical Center

Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditions

United States
Chinese PLA General Hospital

Recruiting

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Mantle Cell Lymphoma | Indolent Non-hodgkin Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

United States
Fujian Medical University

Recruiting

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (A-02)

Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

China
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell Lymphoma | T Cell Lymphoma in Relapse

China
Canadian Cancer Trials Group
AbbVie; Roche Pharma AG; Incyte Corporation

Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Lymphoma, B-Cell

Canada
UNC Lineberger Comprehensive Cancer Center
American Society of Clinical Oncology

Recruiting

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States
Sorrento Therapeutics, Inc.

Recruiting

Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Mycosis Fungoides

United States
Centre Hospitalier Universitaire, Amiens
Institut Bergonié; Centre Henri Becquerel; Saint-Louis Hospital, Paris, France; Henri Mondor University Hospital and other collaborators

Recruiting

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage)

Chemotherapy | Elderly | Diffuse Large B-Cell Lymphoma (DLBCL), Nos

France
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma and Marginal Zone Lymphoma

China
Novartis Pharmaceuticals

Recruiting

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

Japan, Canada
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
UNC Lineberger Comprehensive Cancer Center

Recruiting

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States, Belgium, Australia, Denmark, Italy, Spain, France, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Peking University

Not yet recruiting

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Peripheral T-cell Lymphoma

China
Sun Yat-sen University

Recruiting

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Lymphoma, Large B-Cell, Diffuse

China
University of Alberta
Alberta Cancer Foundation; Canadian Cancer Trials Group

Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)

Relapsed Non Hodgkin Lymphoma | Relapsed Pediatric ALL | Relapsed Adult ALL

Canada
Xynomic Pharmaceuticals, Inc.

Recruiting

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL)

China
Xynomic Pharmaceuticals, Inc.

Recruiting

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

China
Celgene

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Lymphoma, Non-Hodgkin

United States, Korea, Republic of, China, Canada, France, Spain, Denmark, Brazil, Italy, Argentina, Chile, Israel, United Kingdom, Belgium, Austria
Regeneron Pharmaceuticals

Recruiting

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2)

B-cell Non-Hodgkin Lymphoma (NHL)

United States, Korea, Republic of, China, Spain, Japan, United Kingdom, France, Taiwan, Singapore, Italy, Australia, Canada, Germany, Poland
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic Lymphoma

United States
Ottawa Hospital Research Institute

Recruiting

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

Canada
Swedish Medical Center
Acerta Pharma BV

Recruiting

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Diffuse Large B Cell Lymphoma

United States
Samsung Medical Center

Recruiting

Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma (Lemon-T)

Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma

Korea, Republic of
Seoul National University Hospital

Not yet recruiting

Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (EPIC)

Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

Korea, Republic of
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Follicular Lymphoma | Diffuse Large B-cell Lymphoma | CD19-positive

China

Search clinical trials for: relapsed /refractory Hodgkin lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations